BioNTech's Dual Burden: Advancing Oncology Trials While Navigating Berlin's Vaccine Stockpile Fallout
03.06.2026 - 22:31:30 | boerse-global.de
The German biotech is attempting to execute one of the most ambitious corporate pivots in the industry — shifting from a COVID-19 vaccine powerhouse to an oncology leader — but old commitments are proving stubbornly hard to shake. As BioNTech pushes forward with a new Phase 1/2 trial for its bispecific antibody Pumitamig in advanced renal cell carcinoma, the company is simultaneously fielding questions from Berlin about 7.6 million unused vaccine doses and the fate of its domestic production sites.
The ROSETTA RCC-208 study marks a logical expansion for Pumitamig, an antibody that simultaneously blocks PD-L1 and VEGF-A, combining immunotherapy with an anti-angiogenic approach. After demonstrating strong response rates in non-small cell lung cancer at the ASCO 2026 congress, BioNTech is now testing the drug in combination with Arcus Biosciences' HIF-2? inhibitor casdatifan. Bristol Myers Squibb will lead the trial, while each partner retains development and commercialization rights to their respective assets. The scientific rationale — that a therapy showing promise in one solid tumor type can be transferred to another — is backed by parallel progress on the mRNA front. A review in Nature Reviews Drug Discovery highlights the emergence of second-generation mRNA therapeutics, while researchers at the University of Cologne and the Max Planck Institute have elucidated how the proteins SMG5 and SMG6 degrade faulty mRNA, a mechanism critical for developing stable mRNA-based drugs.
Yet the clinical momentum has not translated into share price performance. BioNTech stock trades at around €76.15, having shed roughly 25% of its value over the past twelve months and sitting nearly 28% below its 52-week high of €105.80. The first quarter of 2026 painted a stark picture of the transition: revenues of just €118.1 million against a net loss of €531.9 million, albeit against a cash pile of €16.8 billion. A US dollar-denominated ADS buyback programme of up to $1 billion over twelve months signals management's confidence in the intrinsic value, but operational transformation remains costly.
Should investors sell immediately? Or is it worth buying BioNTech?
The political dimension adds another layer of complexity. Germany's Federal Ministry of Health has confirmed that 7.6 million doses of the updated Comirnaty LP.8.1 vaccine remain in the central federal stockpile, with no further deliveries planned as existing contracts have been fulfilled. More contentious is the potential conflict between BioNTech's announced closure of its German COVID vaccine production sites and a government standby agreement designed to maintain manufacturing capacity for future pandemics. Germany holds similar standby contracts with IDT Biologika and Wacker/Corden Pharma, and the 2026 federal budget allocates €336 million for pandemic preparedness funding, with €175 million pencilled in for 2027. Green party budget politician Paula Piechotta has called for an examination of whether these contracts could be used to compel BioNTech to retain production capacity in Germany — a demand that pits industrial policy against the company's efficiency-driven restructuring.
Jefferies analyst Akash Tewari maintains a "Buy" rating on BioNTech with a price target of $138, citing early oncology data from ASCO. He noted that while the company's non-small cell lung cancer programmes show promise, a clear differentiation from competitor Ivonescimab remains elusive. Longer-term advantages, he argues, will depend on the success of novel combination therapies — exactly the kind of approach being tested in the ROSETTA trial. For now, the company must satisfy both the promise of its pipeline and the demands of a government still mindful of pandemic preparedness, all while the stock price reflects the market's wait-and-see posture. The next clinical data readouts will determine whether the oncology bet can close the gap.
Ad
BioNTech Stock: New Analysis - 3 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
